Stage II Breast Cancer: Diagnosis and Treatment Options - Oncology

Share to:

Stage II breast cancer


Hello Dr.
Lai: I was diagnosed with stage II breast cancer at the end of 2014 and underwent a total mastectomy.
At the same time, there was another tumor about 1 cm on the opposite side, which the doctor assessed as benign through a core needle biopsy, so it was left untreated.
I first addressed the cancerous side and underwent chemotherapy, and I am currently on hormone therapy for ongoing treatment.
At the end of 2015, a breast ultrasound revealed that the previously benign tumor on the other side had increased to about 1.5 cm and had changed to an irregular shape, showing signs of malignancy, and a core needle biopsy was recommended.
My blood cancer markers are currently within the normal range.
I would like to ask: 1.
Is it sufficient to confirm with a mammogram? What are the differences between mammography and breast ultrasound? 2.
If it is benign, is it better to remove it or to continue monitoring it? Thank you for your answers!

Xin Xian, 50~59 year old female. Ask Date: 2016/01/03

Dr. Lai Yicheng reply Oncology


Hello, Miss: 1.
Mammography and breast ultrasound cannot provide a definitive diagnosis; only a pathological biopsy can confirm it with 100% accuracy.
2.
Since you are now 55 years old and postmenopausal, it is still recommended that you undergo a mammogram.
(Premenopausal women have denser breast tissue, which can make mammograms appear whiter and potentially obscure lesions.
Therefore, breast ultrasound is more suitable in those cases.) 3.
I suggest that you first remove the "benign" mass on the other side for a definitive diagnosis, especially since it has increased in size by about 1.5 cm and the imaging has changed to an irregular shape.
Sincerely, Dr.
Lai Yi-Cheng, Radiation Oncology.

Reply Date: 2016/01/03

More Info


Understanding Stage II breast cancer involves recognizing the diagnosis, treatment options, and the implications of findings from imaging and pathology reports. Stage II breast cancer is characterized by a tumor size of 2 to 5 centimeters or smaller tumors with lymph node involvement. In your case, it seems you have undergone a mastectomy and are currently on hormone therapy after chemotherapy, which is a common treatment pathway for hormone receptor-positive breast cancer.

1. Mammography vs. Ultrasound: Mammography and breast ultrasound serve different purposes in breast cancer diagnosis and monitoring. Mammography is an X-ray imaging technique that is particularly effective for detecting calcifications and masses in breast tissue, especially in women over 40. It is less sensitive in women with dense breast tissue, which can obscure the images. On the other hand, breast ultrasound uses sound waves to create images and is excellent for evaluating palpable lumps or abnormalities seen on mammograms. It can provide additional information about the characteristics of a mass, such as its shape and whether it is solid or cystic. In your case, since there is a concern about a previously identified benign tumor that has changed, a combination of both imaging modalities may be beneficial for a comprehensive evaluation.

2. Management of the Benign Tumor: Given that the previously identified tumor has increased in size and has developed irregular characteristics, it is prudent to consider further evaluation, such as a biopsy, to determine its nature. While benign tumors can sometimes be monitored, any changes in size or appearance warrant further investigation. If the biopsy confirms malignancy, surgical intervention may be necessary. If it remains benign but shows concerning features, your healthcare team may recommend surgical removal to eliminate any potential risk of future complications.

In terms of follow-up care, regular monitoring through imaging and clinical exams is essential. The frequency of these evaluations can depend on various factors, including your age, family history, and the specifics of your cancer treatment. Generally, after treatment for breast cancer, follow-up appointments are scheduled every 3 to 6 months for the first few years, transitioning to annual visits thereafter.

It is also important to maintain open communication with your healthcare team. Discuss any concerns you have about your treatment plan, the need for further imaging, or the management of the benign tumor. They can provide personalized recommendations based on your medical history and current health status.

In conclusion, understanding your diagnosis and treatment options is crucial in managing Stage II breast cancer. Regular follow-ups, appropriate imaging, and timely interventions for any changes in your condition are key components of your care. Always feel empowered to ask questions and seek clarity from your medical team regarding your health and treatment journey.

Similar Q&A

Understanding Breast Cancer Surgery and Post-Operative Treatment Options

Hello Doctor, My mother has been undergoing regular mammograms every six months and was diagnosed with breast cancer last week. The tumor is located at the 9 o'clock position in the right breast, measuring 1.2 cm, and is a single tumor (the doctor mentioned that lymph node...


Dr. Lai Yicheng reply Oncology
Dear Madam, Thank you for your letter. Here are my responses: 1. If the malignant tumor is small, partial resection followed by adjuvant radiation therapy can be considered. However, if your mother has multiple benign fibromas in both breasts as you described, total mastectomy ...

[Read More] Understanding Breast Cancer Surgery and Post-Operative Treatment Options


Post-Chemotherapy Management for Stage IIB Breast Cancer Patients

Right breast cancer, with complete mastectomy and axillary lymph node dissection performed. The pathology report is as follows: Stage: IIB, Tumor size: 2.4 cm, Lymph nodes: metastasis present (2, 11), Distant metastasis: none. Tumor type: IDC ER: 90%, PR: 70%, HER-2: negative, Ki...


Dr. Chen Ronghong reply Surgery
Hello, Pang Pang. Currently, in Taiwan, the indications for Atezolizumab are limited to pancreatic cancer, gastric cancer, colorectal cancer, and lung cancer. In Japan, it can be used for unresectable or recurrent breast cancer, but that is different from your situation. Therefor...

[Read More] Post-Chemotherapy Management for Stage IIB Breast Cancer Patients


Post-Surgery Treatment Considerations for HER2-Positive Breast Cancer Patients

1. The patient has stage I breast cancer (Estrogen receptor: negative / Progesterone receptor: negative / HER2: positive / Ki-67: 60%). The postoperative treatment recommendation is to undergo six cycles of chemotherapy combined with targeted therapy using the following three med...


Dr. Chen Jiaming reply Surgery
If there are concerns regarding the treatment in a clinical situation, it is advisable to discuss them with the attending physician, as online consultation information is insufficient to determine the appropriateness of treatment. The imaging reports prior to chemotherapy and the...

[Read More] Post-Surgery Treatment Considerations for HER2-Positive Breast Cancer Patients


Understanding Breast Cancer Treatment Options: Chemotherapy vs. Hormonal Therapy

Hello, doctor. I am 32 years old and have stage II breast cancer. I have undergone a lumpectomy on my left breast. The tumor analysis shows: hormone receptor positive, HER2 negative, and Ki67 at 30%. I would like to know if I definitely need to undergo chemotherapy, or if I can b...


Dr. Lai Yicheng reply Oncology
Dear Ms. Vicky, Thank you for your inquiry. Here is my response: 1. Due to the incomplete information you provided, we can only determine that targeted therapy is not required (HER2 negative / Ki67 50%). This is insufficient to ascertain the need for chemotherapy. - Chemother...

[Read More] Understanding Breast Cancer Treatment Options: Chemotherapy vs. Hormonal Therapy


Related FAQ

Breast Cancer

(Oncology)

Cancer Treatment

(Oncology)

Breast Adenoma

(Oncology)

Terminal Stage

(Oncology)

Axillary Lump

(Oncology)

Breast

(Surgery)

Uterus

(Oncology)

Fibroadenoma

(Breast and Thyroid)

Radiation

(Oncology)

Lymphadenopathy

(Oncology)